EMA Acts On Patient Concerns Over Fluoroquinolone Antibiotics
Executive Summary
Three months after hearing testimonies of patients who suffered severe side-effects from the use of quinolones and fluoroquinolones, the European Medicines Agency has recommended that some of these medicines should be removed from the market and the labeling of others should be changed to restrict their use.
You may also be interested in...
Nabriva Faces Skepticism After Years Of Preparing For Novel Antibiotic Xenleta's Launch
Lefamulin was approved in the US to treat community-acquired bacterial pneumonia, providing a needed IV and oral drug initially in the hospital setting, but new antibiotics have been a tough sell.
42 New Substances Among 84 EU Approval Recommendations In 2018
The EMA’s CHMP recommended EU marketing authorization for a total of 84 new drugs in 2018, containing a total of 42 new active substances. They included the EU’s first two CAR-T cell therapies, Kymriah and Yescarta, which were also among the 21 orphan medicines to gain a positive opinion from the committee.
Two Orphans And An Avastin Biosimilar Among EU Approval Recommendations
Seven new drug applications got the thumbs up this week from the EMA's drug evaluation committee, the CHMP. Their EU approval should now be a formality. Two new Shionogi treatments are set for approval, as are two orphan products – one from Medac, the other from AOP Orphan Pharmaceuticals. Pfizer got the OK for one biosimilar but has withdrawn an application for another.